Last reviewed · How we verify
DTaP vaccine
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.
At a glance
| Generic name | DTaP vaccine |
|---|---|
| Also known as | DTaP vaccine (CJ purified PDT vaccine ™) |
| Sponsor | Sanofi |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated diphtheria and tetanus toxoids (chemically inactivated bacterial toxins) and acellular pertussis antigens, which trigger both humoral and cell-mediated immune responses. This results in the production of protective antibodies and memory immune cells that prevent infection by Corynebacterium diphtheriae, Clostridium tetani, and Bordetella pertussis.
Approved indications
- Prevention of diphtheria in infants and children
- Prevention of tetanus in infants and children
- Prevention of pertussis (whooping cough) in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fussiness or irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTaP vaccine CI brief — competitive landscape report
- DTaP vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI